Targeted Therapy and Emerging Biomarkers for Hepatocellular Carcinoma
Special Issue Editors
Interests: cancer chemoprevention and treatment; breast, lung and ovarian cancers; chemotherapeutic drugs
Special Issues, Collections and Topics in MDPI journals
Interests: Liver cancer; anti-tumor drugs discovery and test; liver cancer biomarker discovery; liver diseases preventive; patient training
Special Issues, Collections and Topics in MDPI journals
Interests: radiotherapy sensitivity and resistance mechanisms; prognostic marker screening and clinical translation; precision radiotherapy and therapy innovation
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) remains a major global health challenge with limited therapeutic options and substantial tumor heterogeneity. Recent advances in molecular profiling have accelerated the development of targeted therapies, immunotherapies, and rational combination strategies that hold promise for overcoming treatment resistance. This Special Issue focuses on current progress in oncogenic signaling pathways, predictive biomarkers for patient stratification, and next-generation therapeutic approaches. We particularly emphasize innovative combination regimens integrating targeted agents with immunotherapy, as well as emerging novel therapies that may transform HCC management. Our goal is to provide a comprehensive forum for cutting-edge research advancing precision oncology and improving clinical outcomes for HCC patients.
Dr. Farrukh Aqil
Dr. Mingdian Tan
Guest Editors
Dr. Yizhi Ge
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- targeted therapy
- emerging biomarkers
- precision oncology
- immunotherapy
- combination therapy
- molecular pathways
- drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
